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Summary
Objective: To investigate the role of tumor necrosis factor stimulated gene 6 (TSG-6) and metal ions in the coupling of inter--trypsin inhibitor
(ITI) to hyaluronan in human synovial fluid.
Design: The concentration of ITI heavy chains bound to hyaluronan was determined by a two-step electrophoretic technique. Synovial fluid,
TSG-6 depleted synovial fluid and metal chelated synovial fluid were tested for their ability to support the coupling of ITI heavy chains to
hyaluronan.
Results: When synovial fluid was mixed with an ITI-source (serum or purified ITI), coupling of ITI heavy chains to hyaluronan took place.
TSG-6 immunodepleated synovial fluid lost the coupling activity, but addition of recombinant TSG-6 restored the activity. EDTA inhibited the
coupling activity, but combinations of the metal-ion chelators Mg-EGTA and Ca-EGTA demonstrated, that Ca++ is essential for the coupling
of ITI heavy chains to hyaluronan.
Conclusions: Tumor necrosis factor stimulated gene 6 (TSG-6) and calcium ions are both essential for the coupling of inter--trypsin inhibitor
to hyaluronan in human synovial fluid.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Hyaluronan is of great significance for the hydrodynamic
and viscoelastic properties of synovial fluid and is therefore
considered to be responsible for the lubricating and shock-
absorbing properties of synovial fluid1. Hyaluronan is a high
molecular weight linear polysaccharide, and in synovial
fluid it forms an entangled network throughout the solution.
Small molecules like water and inorganic ions can diffuse
unhindered through the network, while large molecules and
cells are excluded or restricted in their free migration by the
hyaluronan network2. Hyaluronan is synthesized by hy-
aluronan synthase isoenzymes, HAS1, HAS2 and HAS33
located in fibroblastic synovial lining cells, from where it is
excreted into the synovial cavity.
Proteins in synovial fluid are mainly derived from the
blood plasma. The mean concentration of plasma proteins
in normal human synovial fluid is 13 g/l4. The plasma
proteins enter the joint space by infiltration from the blood-
stream across the synovial barrier and they return to the
circulation through lymphatic vessels5. One plasma protein,
inter--trypsin inhibitor (ITI), is known to form firm com-
plexes with hyaluronan6,7. ITI being synthesized in the
liver8, is a protein with a unique structure consisting of
polypeptide chains covalently crosslinked by carbohy-
drate9. Two heavy chains H1 (Mr 65 kDa) and H2 (Mr
70 kDa) and one light chain named bikunin (Mr 30 kDa) are
linked together by chondroitinsulfate10. In synovial fluid
inter--trypsin inhibitor exists both free in the solution and
bound to the hyaluronan network6. The ITI fraction bound
to hyaluronan consists only of ITI heavy chains coupled by
covalent bindings to hyaluronan7. The unbound ITI fraction
include bikunin and other ITI metabolites6. Therefore, one
or more metabolic processes in the synovial fluid must
transform the infiltrated plasma ITI into ITI heavy chains
coupled to hyaluronan, and to unbound bikunin. The heavy
chains is supposed to be transferred to hyaluronan by a
transester reaction7,but the molecular mechanism leading
to the biological coupling of ITI heavy chains to hyaluronan
are only partly resolved.
In-vitro incubation of ITI with hyaluronan does not lead to
formation of firm complexes between ITI heavy chains and
hyaluronan11. Recent investigations of an analogous bind-
ing reaction between ITI and hyaluronan in human follicular
fluid have shown that calcium ions and tumor necrosis
factor stimulated gene 6 protein (TSG-6) are essential
components for the coupling of ITI heavy chains to
hyaluronan12,13.
Human tumor necrosis factor stimulated gene 6 (TSG-6)
originally cloned from human fibroblasts, encodes a 277
amino acid prepropeptide that is secreted as a glycoprotein
with a Mr of 35 000. TSG-6 is expressed in many cell types
including synovial cells, chondrocytes, mononuclear cells
and fibroblasts, and high levels of TSG-6 protein are found
in synovial fluids of patients with rheumatoid arthritis (RA),
*Address correspondence to: Torben Ehlern Jessen, Depart-
ment of Clinical Biochemistry, Diagnostic Center, Sygehus
Vestsjælland, DK-4300 Holbæk, Denmark. Tel.: +45-59484403;
Fax: +45-59484409; E-mail: chtoje@vestamt.dk
Received 14 July 2003; revision accepted 4 October 2003.
International
Cartilage
Repair
Society
OsteoArthritis and Cartilage (2004) 12, 142–148
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.joca.2003.10.004
142
osteoarthritis, Sjo¨gren′s syndrome, polyarthritic gout and
osteomyelitis14–16. The expression of TSG-6 is induced by
cytokines such as tumor necrosis factor- and interleukin-
117. TSG-6 has an anti-inflammatory activity and up-
regulation of the gene as well as therapeutic injections of
recombinant TSG-6 reduces symptoms of inflammation
and joint destruction in mouse models17–19.
These observations made it relevant to investigate if
TSG-6 and calcium ions in synovial fluid are involved in the
coupling of ITI to hyaluronan, like in follicular fluid12. As
demonstrated in the present work this was in fact the case:
TSG-6 antibodies and calcium chelating agents blocked
the coupling activity of synovial fluid, and subsequent
addition of recombinant TSG-6 protein and free calcium
ions, respectively, to depleted synovial fluid restored the
activity, showing that both TSG-6 and calcium ions are
necessary for the coupling of ITI to hyaluronan.
Materials and methods
REAGENTS AND CHEMICALS
Ovine testicular hyaluronidase (EC 3.2.1.35, specific
activity 49 130 national formulary (N.F.) units (as defined in
United States Pharmacopeia) per mg protein, (art.
no. 38 594) and human umbilical cord hyaluronic acid (art.
no. 385 902) were obtained from Calbiochem (Nova-
biochem Corporation, Darmstadt). Rabbit anti-human ITI
immunoglobulin directed against all peptides of ITI (that is,
Bikunin, heavy chain 1 and heavy chain 2) was obtained
from Dako A/S (Copenhagen; code A 301)6. Trypsin from
bovine pancreas (activity: 12700 benzoyl-L-arginine ethyl
ester (BAEE) units per mg, T-8253) (one BAEE unit=A253 of
0.001 pr. min with BAEE substrate at pH 7.6 at 25°C), and
soybean trypsin inhibitor (activity: 1.6 mg will inhibit 1.6 mg
trypsin, T-9003) were obtained from Sigma (Aldrich Chemie
Gmbh, Steinheim). Agarose LSL 4000 was obtained from
FMC BioProducts (Rockland, ME). ITI was purified from
serum using the method described by Jochum and
Bittner20 and appeared on SDS-PAGE as a single band
with Mr 240 kDa (not shown). Recombinant TSG-6 pro-
tein21 and rabbit antibodies directed against TSG-6 were
kindly provided by Hans-Georg Wisniewski (DNYU School
of Medicine; Department of Microbiology; 550 First Avenue;
New York, NY 10016). Immunoprecipitated human synovial
fluid were obtained by addition of TSG-6 antibodies to a
pool of human synovial fluid followed by incubation 18 h at
4°C, and centrifugation (14 000 g, 15 min). The amount of
anti-TSG-6 added was adjusted to give a supernatant
devoid of TSG-6. Trypsin digestion was prepared by mixing
synovial fluid (1000 µl) with 100 µl phosphate buffer
(50 mmol l-1, pH 8.0) containing 10 mg trypsin ml-1. After
incubation at 37°C for 6 h, 100 µl soybean trypsin
inhibitor (10 mg ml-1 in phosphate buffer) were added.
Hyaluronidase-digested bikunin was prepared by incubat-
ing partly purified bikunin (200 mg l-1)22 with ovine testicu-
lar hyaluronidase (2000 U ml-1). The metal ion
chelators ethylenediaminetetraacetic acid (EDTA) and
ethyleneglycol-bis(-aminoethylether)-N,N,N′,N′-tetraacetic
acid (EGTA) as well as all other reagents and chemicals
were of analytical grade.
SAMPLES
Synovial fluids were kindly donated by Dr Michael
Sonne, Department of Rheumatology, Roskilde University
Hospital, DK-4000 Roskilde. Synovial fluids were from
patients with RA treated for effusions of the knee-joint.
Synovial fluids were collected in tubes without anticoagu-
lants and centrifuged at 3000 g for 10 min before use.
Pools of synovial fluids were made by mixing equal
amounts of synovial fluids from 5 to 10 patients.
DEMONSTRATION OF COUPLING ACTIVITY BY
IMMUNOELECTROPHORESIS
Experiments were performed by mixing the following
components: (i) ITI source: one volume of normal human
serum (ITI concentration=1 U ml-1) or purified ITI (0.8 U
ml-1 or 1.5 U ml-1), (ii) buffer: one volume of 45 mmol
Tris-HCl l-1, pH 7.4, 4.5 mmol CaCl2 l-1, 150 mmol NaCl l-1,
4.5 mg hyaluronan ml-1, with or without 9 µg or 36 µg
TSG-6 ml-1, (iii) synovial fluid: one volume of human or
immunoprecipitated human synovial fluid. In some exper-
iments synovial fluid or the ITI-source was replaced with
saline. The mixtures were incubated at 37°C. Aliquots were
withdrawn (0, 3, 24 and 42 h), and 1.5 mol NaCl l-1 (one
third of the withdrawn volume) was added before storing at
−20°C. The visualization of hyaluronan bound (immobi-
lized) heavy chains was performed by a two-step electro-
phoresis6,23. Heavy chains bound to hyaluronan were
retained in the application well during removal of unbound
proteins by electrophoresis. The retained hyaluronan was
then degraded and the released hyaluronan-bound pro-
teins detected by electrophoresis in an antibody-containing
gel. In step 1, separation electrophoresis of 10 µl samples
was carried out at 10-volt cm-1 for 60 min in a 1.5 mm thick
horizontal 1% agarose gel. After electrophoresis, sample
wells were treated with testis hyaluronidase (50 U per well,
1 h, 37°C) to release hyaluronan-bound proteins. In step 2,
after digestion of hyaluronan in sample wells, the gel at the
anodic side of the wells containing the anodic migrating
proteins of the first run was replaced by anti-ITI gel (1.1 µl
cm-2). Electro-immunoassay of the ITI polypeptides re-
leased by hyaluronidase treatment was run overnight at
2.5 V cm-1 into the anti-ITI gel24. The concentration of ITI
heavy chains bound to hyaluronan is expressed in mU ml-1,
where 1 U correspond to the total amount of ITI heavy
chains in 1 ml normal human serum23.
All experiments have been performed at least twice.
Results
OCCURRENCE OF COUPLING ACTIVITY
Coupling activity was present in synovial fluid (Fig. 1,
lane 1–4) expressed as increasing amounts of HC-
hyaluronan complexes formed during 42 h after mixing of
human synovial fluid, human serum and hyaluronan. The
ITI immunoprecipitates seen at 0 h (Fig. 1 lane 1, 5, 9) is
due to in vivo preformed ITI-hyaluronan complexes in
human synovial fluid plus the ITI bound to hyaluronan in the
few minutes from mixing of the reactants to the aliquots
were frozen. When serum was replaced by purified ITI,
similar results were seen (Fig. 1 lane 5–8), but coupling of
ITI to hyaluronan reached a maximum after 3 h of incu-
bation, probably due to exhaustion of the ITI-source. No
coupling took place if the ITI-source was omitted, i.e.
mixing only synovial fluid and hyaluronan (Fig. 1 lane
9–12). The ITI released from the electrophoresis wells after
hyaluronidase treatment showed antigenic non-identity with
bikunin and are therefore referred to as heavy chains (HC)
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(Fig. 1 lane 1–4), i.e. the weak horizontal precipitation line
passes the rockets without interaction. Only when using
purified ITI (Fig. 1 lane 5–8) a weak deflection of the
precipitation line is seen (mostly in lane 5 & 6) suggesting
that the ITI hyaluronan complexes shortly after their forma-
tion contain some bikunin.
Mixing solely serum or ITI with hyaluronan did not result
in formation of HC hyaluronan complexes (Table I, exper-
iment 1 & 2). Only when synovial fluid was mixed with an
ITI-source (serum or purified ITI), coupling took place
(Table I, experiment 4–7). The fact that addition of purified
ITI to synovial fluid leads to formation of ITI hyaluronan
complexes (Table I, experiment 4) demonstrates that the
pool of synovial fluid from RA patients contains all the
substances needed for coupling, except ITI. Synovial fluid
must therefore contain hyaluronan in excess, accessible to
take part in further coupling of ITI. However, synovial fluid
must also contain unidentified factors involved in the coup-
ling reaction. A pre-treatment of synovial fluid with trypsin
destroyed the coupling activity (Table I experiment 8),
suggesting that a protein factor in synovial fluid is involved
in the coupling.
INVOLVEMENT OF TSG-6 IN THE COUPLING REACTION
Synovial fluid was incubated with polyclonal rabbit anti-
bodies directed against human TSG-6 protein in order to
immunoprecipitate TSG-6.
After immunoprecipitation, coupling activity decreased in
a dose dependent manner (Fig. 2) and addition of anti
TSG-6 antibody diluted 1:2 completely inhibited the coup-
ling activity, i.e. the immunoprecipitates did not increase in
size showing that no ITI-heavy chain were coupled to
hyaluronan during the incubation period.
However, if recombinant TSG-6 was subsequently added
to the immunopreciptated synovial fluid (Fig. 3), the coup-
ling activity was restored in a dose-response manner
(Fig. 3 lane 7–12) using 3 µg/ml or 6 µg/ml TSG-6. Conse-
quently, TSG-6 must be essential for the coupling of ITI to
hyaluronan in synovial fluid.
Fig. 1. Demonstration of coupling activity in synovial fluid. Complexes between ITI and hyaluronan were demonstrated by the 2
step-immuno-electrophoresis by which hyaluronan and hyaluronan bound proteins are retained in the electrophoretic wells. Following
removal of unbound proteins, hyaluronan bound proteins were released by enzymatic degradation of hyaluronan, and ITI was visualized as
‘rocket’ immunoprecipitates by electrophoresis into an anti-ITI containing gel. Before the final ‘rocket’ immunoelectrophoresis, a narrow
(5 mm) intermediate gel containing 8 µl purified bikunin (200 mg l-1) was placed between the anti ITI gel and the sample wells, to give a
horizontal precipitation line. Lane 1–4: Coupling activity in the presence of serum and synovial fluid: control experiment with mixture of
human synovial fluid, hyaluronan and human serum incubated for 0, 3, 24 and 42 h. Lane 5–8: Coupling activity in the presence of purified
ITI and synovial fluid: as in lane 1–4, but with human serum substituted by purified ITI (0.8 U ml-1). Lane 9–12: No coupling activity in synovial
fluid without exogenous ITI: as in lane 1–4, but with human serum substituted by saline.
Table I
Components required for formation of heavy chain-hyaluronan
complexes
Heavy chains
(mU ml-1)
bound to
hyaluronan
after
Experiment Component 0 h 3 h 24 h
1 Hyaluronan+serum 0 0 0
2 Hyaluronan+ITI* 0 0 0
3 Synovial fluid+hyaluronan 90 98 80
4 Synovial fluid+ITI* 116 135 275
5 Synovial fluid+serum 108 145 183
6 Synovial fluid+ITI*+hyaluronan 118 129 237
7 Synovial fluid+serum+hyaluronan 98 129 188
8 Synovial fluid†+serum+hyaluronan 89 79 71
*ITI concentration=1.5 U ml-1.
†Human synovial fluid pre-treated with trypsin.
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To test the influence of Calcium ions known to be
essential in follicular fluid, 10 mM EDTA was added to
remove free Ca++. As seen in Fig. 4 (lane 4–6) this blocked
the coupling activity. To further characterize the necessary
ion Mg-EGTA (lane 7–9) was added. Mg-EGTA will chelate
Ca++, Fe++, Fe+++, Zn++ and Cu++, but allow free Mg++. No
coupling was seen in this case. Addition of Ca-EGTA (lane
10–12) chelates Fe++, Fe+++,Zn++ and Cu++, but allow free
Ca++ and Mg++. In this case the coupling activity of synovial
fluid was maintained, showing that Ca++ is essential for the
coupling reaction in synovial fluid.
Discussion
The focus of ITI binding to hyaluronan has in the last few
years been on normal oocyte development and ovulation25
as ITI is necessary for normal fertility26. The binding of ITI
to hyaluronan was first discovered in pathological synovial
fluid27, but it is not until the last decade that attention has
been drawn to the similarities between the coupling of ITI to
hyaluronan in synovial fluid and follicular fluid6.
One important question is: does ITI simply bind to
hyaluronan if it gets access to body-compartments with
hyaluronan or is other components necessary? When our
binding assay was performed at physiological salt concen-
tration, we observed no binding by mixing only ITI and
hyaluronan. Addition of synovial fluid to the reaction mixture
generated complexes between ITI and hyaluronan pro-
gressing over a period of hours, as demonstrated in Fig. 1.
As we found no coupling of ITI to hyaluronan if synovial
fluid was substituted by normal human serum, we con-
cluded that synovial fluid must contain at least one compo-
nent distinct from normal plasma constituents, but essential
for the coupling reaction.
For the binding to take place in follicular fluid, ITI, and
Ca++ plus hyaluronan and TSG-6 supplied by follicular fluid
must be present together to form stable complexes12.
TSG-6 is an anti-inflammatory protein28 detected both in
synovial fluid of arthritic patients14 and in ovarian follicles
that have been induced to ovulate29.
In the present study we have demonstrated that TSG-6
and Ca++ are necessary for the coupling of ITI to hyaluro-
nan in synovial fluid. This is in accordance with the recently
discovered role of TSG-6 in follicular fluid as mentioned
above12. The molecular mechanism behind the coupling of
ITI to hyaluronan and the role of TSG-6 and Ca++ in this
biochemical reaction is not fully understood. TSG-6 is,
however, known both as a hyaluronan binding and an ITI
binding protein21, and one possible function of TSG-6 in the
coupling reaction might therefore be to establish contact
between ITI and hyaluronan as a first step in the coupling
reaction. A cross-linking of hyaluronan could be established
by a possible secondary displacement of bikunin and the
chondroitin sulphate chain in a trans-ester reaction leading
to the formation of an ester bond between the C-terminal
aspartate of HC and hyaluronan7.
There are many similarities between the coupling of ITI to
hyaluronan in synovial fluid and in follicular fluid. Both
reactions take place in the extra-cellular space of the body
compartment in question with an internal synthesis of
hyaluronan and TSG-6, and an external supply of ITI from
the blood circulation. In both cases the reaction is depen-
dent on calcium ions, and the final coupling product con-
sists of ITI heavy chains without bikunin. Recently reported
experiments12 showed that incubation of Hyaluronan,
TSG-6, and Ca++ with purified ITI did not lead to coupling of
ITI to hyaluronan. Synovial fluid and follicular fluid may
therefore contain unidentified components essential for the
Fig. 2. Coupling activity in synovial fluid is removed by anti-TSG 6. Lane 1–3: Coupling activity in the presence of serum and synovial fluid:
control experiment with mixture of human synovial fluid, hyaluronan and human serum incubated for 0, 3 and 24 h. Lane 4–6:
Immunoprecipitation with anti TSG 6 (diluted 1:8): as in lane 1–3, but after pre-treatment of synovial fluid with anti-TSG 6. Lane 7–9:
Immunoprecipitation with anti TSG 6 (diluted 1:4): as in lane 1–3, but after pre-treatment of synovial fluid with anti-TSG 6. Lane 10–12:
Immunoprecipitation with anti TSG 6 (diluted 1:2): as in lane 1–3, but after pre-treatment of synovial fluid with anti-TSG 6.
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coupling reaction, or the lack of coupling might be due to
non-optimal reaction conditions.
We find it most likely to be the same reaction mechanism
behind the coupling of ITI to hyaluronan in synovial fluid
and follicular fluid. There are, however, differences be-
tween the coupling potential of synovial fluid and follicular
fluid. In synovial fluid from RA patients, ITI seems to be the
limiting component in the coupling reaction, as purified ITI
added to synovial fluid causes further coupling of ITI heavy
chains to hyaluronan. In follicular fluid no further coupling is
generated when ITI is added, but addition of hyaluronan to
follicular fluid causes further coupling11. Therefore, the
influx of ITI to the synovial cavity seems to be the limiting
factor for the coupling of ITI to hyaluronan in synovial
fluid from RA patients, while intrafollicular synthesis of
hyaluronan seems to be the limiting factor in preovulatory
follicles.
The physiological function of the coupling of ITI heavy
chains to hyaluronan is much better understood in the
ovaries than in joints. A profound expansion of the cumulus
cell-oocyte complex (COC) in the follicle takes place just
before ovulation. The COC is a mucilaginous network of
hyaluronan, hyaluronan producing cumulus cells, ITI heavy
chains and TSG-630. In-vitro experiments have shown that
when ITI is not present at the time of COC expansion, the
hyaluronan network surrounding the ovum cannot maintain
its integrity, and no stable COC matrix is obtained31. In
agreement with this, in-vivo experiments have shown that
female mice lacking ITI are infertile, but infertility can be
reversed by injection of ITI26,32. Deficiency of TSG-6
appears to have the same consequences. Female mice
lacking TSG-6 are sterile, and fail to produce expanded
COC, but fertility is regained by injection of recombinant
TSG-613. Thus both ITI and TSG-6 are indispensable for
female fertility, and the important role of the two proteins in
the ovulation process seems to be a stabilization of the
COC and an incorporation of newly synthesized hyaluro-
nan molecules into the expanding hyaluronan network of
the COC.
The physiological function of the hyaluronan network in
synovial fluid is considered to be of great importance for its
high viscosity and for its lubricating and shock-absorbing
functions2. TSG-6 is an acute phase protein15 and one
might speculate if the formation and maintenance of the
ITI-hyaluronan network are of especially importance in
inflammatory joint disorders with influx of plasma and joint
swelling. In various models of experimentally induced ar-
thritis TSG-6 is reported to exhibit a strong anti inflamma-
tory and chondroprotective effect preventing cartilage
proteoglycan from metalloproteinase-induced degrada-
tion18,19,33. Thus, in inflamed joints TSG-6 could be import-
ant both due to its anti-inflammatory and chondroprotective
activity, but also in collaboration with ITI through stabiliz-
ation and rebuilding of the hyaluronan network in order to
maintain the rheological properties of the synovial fluid.
Intra-articular injections of native hyaluronan or a cross-
linked hyaluronan derivative have been used in the treat-
ment of patients with osteoarthritis to relieve pain and
improve the function of the knee34. Inflammatory symptoms
are reduced, and the rheological properties of synovial fluid
are to some degree restored by this treatment35. Since the
concentration of TSG-6 is raised in inflamed joints, a
combination of hyaluronan and ITI might be a far more
effective therapeutic agent compared to pure hyaluronan,
because the coupling of ITI heavy chains to hyaluronan
in inflamed joints seems according to this study mainly
to be limited by the influx of plasma ITI into the synovial
cavity.
Fig. 3. Restoration of coupling activity in immunoprecipitated synovial fluid by addition of recombinant TSG 6. Lane 1–3: Coupling activity in
the presence of serum and synovial fluid: control experiment with mixture of human synovial fluid, hyaluronan and human serum incubated
for 0, 3 and 24 h. Lane 4–6: Immunoprecipitation of synovial fluid with anti TSG 6 (diluted 1:2): as in lane 1–3, but after pre-treatment of
synovial fluid with anti-TSG 6. Lane 7–9: Addition of TSG 6 to immunoprecipitated synovial fluid: as in lane 4–6, but with addition of TSG 6
(3 µg/ml). Lane 10–12: Addition of TSG 6 to immunoprecipitated synovial fluid: as in lane 4–6, but with addition of TSG-6 (12 µg/ml).
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In conclusion, the present study shows that TSG-6 and
calcium ions are both necessary for the coupling of ITI to
hyaluronan.
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